Synendos Therapeutics AG

Synendos is a clinical stage neuroscience company developing breakthrough safe and effective therapies for neuropsychiatric disorders such as PTSD, through modulation of a new drug target that enables restoration of the natural functioning of the brain. Our lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). Pre-clinical development of SYT-510 has been successfully completed, the CTA has been approved by the EMA and the first Phase 1 clinical trial has begun in early 2024. We plan to validate the potential of this novel mode of action through completion of early clinical development including a Proof-of-Concept study in patients.